Cargando…

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2

Chimeric antigen receptors (CAR) and bispecific antibodies (BsAb) are two powerful immunotherapy approaches for retargeting lymphocytes toward cancer cells. Despite their success in lymphoblastic leukemia, solid tumors have been more recalcitrant. Identifying therapeutic barriers facing CAR-modified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoseini, Sayed Shahabuddin, Dobrenkov, Konstantin, Pankov, Dmitry, Xu, Xiaoliang L., Cheung, Nai-Kong V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486173/ https://www.ncbi.nlm.nih.gov/pubmed/28680755 http://dx.doi.org/10.1080/2162402X.2017.1320625

Ejemplares similares

Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
por: Reppel, Loïc, et al.
Publicado: (2022)

Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2
por: Ahmed, Mahiuddin, et al.
Publicado: (2014)

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
por: Cheng, Ming, et al.
Publicado: (2016)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells
por: Wu, Dianna Y., et al.
Publicado: (2003)

Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
por: Erber, Ramona, et al.
Publicado: (2021)

Label-free in vitro assays predict the potency of anti-disialoganglioside chimeric antigen receptor T-cell products
por: Logun, Meghan, et al.
Publicado: (2023)

Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
Publicado: (1986)

Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2
por: Müller, Jan, et al.
Publicado: (2016)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
por: Nazha, Bassel, et al.
Publicado: (2020)

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
por: Park, Jeong A., et al.
Publicado: (2020)

Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin
por: Inagaki, Fuyuki F., et al.
Publicado: (2022)

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2021)

Disialoganglioside GD2 distributes preferentially into substrate- associated microprocesses on human melanoma cells during their attachment to fibronectin
Publicado: (1986)

Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD(2) Coated Nanoparticles
por: Tivnan, Amanda, et al.
Publicado: (2012)

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
por: Yankelevich, Maxim, et al.
Publicado: (2023)

An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2
Publicado: (1987)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
por: Santich, Brian H., et al.
Publicado: (2020)

Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors
por: Golinelli, Giulia, et al.
Publicado: (2018)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
por: Strohl, William R., et al.
Publicado: (2019)

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
por: Becker, Scott A., et al.
Publicado: (2023)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
por: Anderson, John, et al.
Publicado: (2023)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
por: Yu, Jiayi, et al.
Publicado: (2018)

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies
por: Park, Jeong A, et al.
Publicado: (2022)

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
por: Stone, Jennifer D., et al.
Publicado: (2012)

Dual targeting of the tumor and its associated vasculature using a single bispecific chimeric antigen receptor molecule
por: Byrd, Tiara, et al.
Publicado: (2014)

Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
por: Markouli, Mariam, et al.
Publicado: (2023)

Pharmacokinetics of the disialoganglioside, G(D2), a circulating tumor biomarker for neuroblastoma, in nonhuman primates
por: Balis, Frank M., et al.
Publicado: (2021)

GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction
por: Sujjitjoon, Jatuporn, et al.
Publicado: (2020)

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients
por: Yu, Lihua, et al.
Publicado: (2021)

Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
por: Larrosa, Cristina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e8mqbtrnofk1cb6l9lno74b2ov